BackgroundCheck.run
Search For

Jean Jui Chu ShihPasadena, CA

Jean Shih Phones & Addresses

San Marino, CA   

Westlake Village, CA   

335 Arbolada Dr, Arcadia, CA 91006    626-8368969   

924 Winston Ave, San Marino, CA 91108   

Mentions for Jean Jui Chu Shih

Jean Shih resumes & CV records

Resumes

Jean Shih Photo 33

Jean Shih

Publications & IP owners

Us Patents

Monoamine Oxidase Inhibitors And Methods For Treatment And Diagnosis Of Prostate Cancer

US Patent:
2013003, Feb 14, 2013
Filed:
Jul 26, 2012
Appl. No.:
13/559431
Inventors:
Jean C. SHIH - Beverly Hills CA, US
Leland CHUNG - Los Angeles CA, US
Haiyen E. ZHAU - Los Angeles CA, US
Boyang Jason WU - Los Angeles CA, US
Bogdan Z. OLENYUK - Sierra Madre CA, US
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA
International Classification:
A61K 31/405
C07D 319/18
C07D 311/36
C07D 311/54
A61K 31/381
A61K 31/357
A61K 31/352
A61K 31/366
A61K 31/7088
A61K 31/713
A61K 31/404
C07D 209/14
C07D 409/14
C12N 9/99
C12Q 1/26
A61K 49/00
G01N 33/574
C12Q 1/68
A61P 35/00
C07D 333/28
US Classification:
424 91, 549 78, 549362, 549403, 549285, 514438, 514452, 514456, 514414, 514 44 A, 548455, 435184, 435 25, 435 74, 435 612
Abstract:
A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.

Monoamine Oxidase Inhibitors And Methods For Treatment And Diagnosis Of Prostate Cancer

US Patent:
2018017, Jun 28, 2018
Filed:
Feb 23, 2018
Appl. No.:
15/904103
Inventors:
- Los Angeles CA, US
Jean C. SHIH - Beverly Hills CA, US
International Classification:
A61K 31/5375
A61K 31/357
A61K 45/06
A61K 31/381
A61K 31/366
A61K 31/405
A61K 31/15
A61K 49/16
A61K 31/138
A61K 31/4188
A61K 31/352
A61K 31/4045
C07D 209/24
A61K 31/137
C12N 15/113
A61K 31/135
A61K 31/495
Abstract:
A method of treating prostate cancer in a subject with biochemically recurrent prostate cancer is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes phenelzine.

Mao Inhibitors And Their Conjugates As Therapeutics For The Treatment Of Brain Cancer

US Patent:
2017002, Feb 2, 2017
Filed:
Oct 13, 2016
Appl. No.:
15/293055
Inventors:
Jean C. Shih - Beverly Hills CA, US
Florence M. Hoffman - Venice CA, US
Thomas C. Chen - La Canada Flintridge CA, US
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA
International Classification:
C07D 209/14
Abstract:
A pharmaceutical composition and method for treating brain cancer are provided. The method includes administering to a patient in need thereof an effective amount of one or more compounds that include moclobemide, clorgyline, clorgyline's Near-infra-red dye Monoamine Oxidase Inhibitor (NMI), and MHI 148-clorgyline, and their salt thereof. The composition and method are particularly effective in reducing the size of glioblastomas that are temozolomide (TMZ) resistant.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.